Professor Claus Rödel

Claus Rödel (born 3.2.1966) graduated from Erlangen Medical School, Germany, in 1994, and completed his medical speciality training degree in Radiation Oncology in 2002. He was attending physician and consultant at the Department of Radiation Therapy, University of Erlangen, Germany, until 2006. In 2007, he was appointed Director and Chair of the Department of Radiotherapy and Oncology at the University of Frankfurt, Germany. Since 2008, he also serves as Clinical Director of the Comprehensive Cancer Center (UCT) of the University Hospital of Frankfurt, and is a principal investigator within the German Cancer Consortium (DKTK). His main research interests focus on combined modality treatment, including targeted therapies, for patients with rectal and bladder cancer, as well as molecular prediction of tumor response. As Speaker of the German Rectal Cancer Study Group he led several phase I-III clinical trials to establish and optimize chemoradiotherapy for rectal cancer patients. His scientific work has been honoured with the Herman-Holthusen Award of the German Society of Radiation Oncologist (DEGRO), the Clinical Science Award of ARO, the German Cancer Society’s (DKG) Award for the best clinical trial in 2015, and the Breur Award of ESTRO (2017). He also serves as member of the ESTRO Clinical Committee and Director of the ESTRO Teaching Course for lower gastrointestinal cancers.